Subarachnoid transplantation of autologous neurogenically induced bone marrow derived mesenchymal stem cells for the treatment of fibrocartilaginous embolic myelopathy in two dogs

Abstract

The objective of this study was to investigate the effects of autologous neurogenically induced bone marrow-derived mesenchymal stem cells (NIBM-MSCs) in two dogs suspected to have fibrocartilaginous embolic myelopathy (FCEM). Both dogs were paraplegic without deep pain perception (DPP) and tentatively diagnosed by MRI. Autologous NIBM-MSCs (5 × 106) were transplanted into the lumbar subarachnoid space two times with a 21-day interval for each patient. Based on a 21-month follow-up of the treated animals, the transplantation of NIBM-MSCs seems to be promising in subjects with FCEM lacking DPP.